Lyell Immunopharma, Inc.LYELEarnings & Financial Report
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company specializing in the research and development of next-generation chimeric antigen receptor (CAR) T cell therapies to treat various solid tumors. It primarily targets oncology patient segments across North America, focusing on addressing unmet medical needs in hard-to-treat cancer types.
LYEL Q4 FY2025 Key Financial Metrics
Revenue
$6.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-45.5%
Lyell Immunopharma, Inc. Q4 FY2025 Financial Summary
Lyell Immunopharma, Inc. reported revenue of $6.0K (down 45.5% YoY) for Q4 FY2025, with a net profit of N/A (up 26.7% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $6.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Lyell Immunopharma, Inc. Annual Revenue by Year
Lyell Immunopharma, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $36.0K).
Lyell Immunopharma, Inc. Quarterly Revenue & Net Profit History
Lyell Immunopharma, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $6.0K | -45.5% | N/A | N/A |
| Q3 FY2025 | $15.0K | -55.9% | $-38.8M | -258973.3% |
| Q2 FY2025 | $8.0K | -38.5% | $-42.7M | -533550.0% |
| Q1 FY2025 | $7.0K | +133.3% | $-52.2M | -745642.9% |
| Q4 FY2024 | $11.0K | -15.4% | N/A | N/A |
| Q3 FY2024 | $34.0K | +36.0% | $-44.6M | -131126.5% |
| Q2 FY2024 | $13.0K | -51.9% | $-45.8M | -352376.9% |
| Q1 FY2024 | $3.0K | -95.4% | $-60.7M | -2022233.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3000 | $13000 | $34000 | $11000 | $7000 | $8000 | $15000 | $6000 |
| YoY Growth | -95.4% | -51.9% | 36.0% | -15.4% | 133.3% | -38.5% | -55.9% | -45.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $694.2M | $654.1M | $619.2M | $490.9M | $429.8M | $385.5M | $408.0M | $340.1M |
| Liabilities | $91.1M | $87.6M | $88.5M | $108.0M | $93.3M | $86.5M | $78.8M | $91.8M |
| Equity | $603.2M | $566.5M | $530.7M | $382.8M | $336.5M | $298.9M | $329.1M | $248.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-42.0M | $-38.1M | $-35.0M | $-162.4M | $-54.7M | $-34.5M | $-28.6M | $-150.0M |